Abstract
Alzheimer’s disease (AD) is the most frequent cause of dementia due to neurodegeneration. It is stated that the most important risk factor for the late onset AD development is age. AD develops during decades and appears most of the time after 65 years of age. Even though its incidence is increasing with age but not all the centenarians are suffering from AD. The most important underlying age-related factor is immunosenescence/inflammaging. Indeed, aging is associated with immune changes which are thought to be the most prevalent cause of the age-related chronic inflammatory diseases. However, it is now postulated that the changes occurring with aging in the immune system may not be only detrimental but also adaptive. Therefore, in this review we will describe whether and how immunosenescence/inflammaging may contribute to the development of AD. We will also examine whether this can lead to novel treatment approaches different form the current.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer’s disease. Neurobiol Aging May–June 2021;21(3):383–421. https://doi.org/10.1016/s0197-4580(00)00124-x
Arai Y, Martin-Ruiz CM, Takayama M, Abe Y, Takebayashi T, Koyasu S, Suematsu M, Hirose N, von Zglinicki T (2015) Inflammation, but not telomere length, predicts successful ageing at extreme old age: a longitudinal study of semi-supercentenarians. EBioMedicine 2(10):1549–1558. https://doi.org/10.1016/j.ebiom.2015.07.029
Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzériat K, Dansokho C, Dierkes T, Gelders G, Heneka MT, Hoeijmakers L, Hoffmann A, Iaccarino L, Jahnert S, Kuhbandner K, Landreth G, Lonnemann N, Löschmann PA, McManus RM, Paulus A, Reemst K, Sanchez-Caro JM, Tiberi A, Van der Perren A, Vautheny A, Venegas C, Webers A, Weydt P, Wijasa TS, Xiang X, Yang Y (2017) Targeting neuroinflammation to treat Alzheimer’s disease. CNS Drugs 31(12):1057–1082. https://doi.org/10.1007/s40263-017-0483-3
Arts RJ, Joosten LA, Netea MG (2016) Immunometabolic circuits in trained immunity. Semin Immunol 28:425–430
Atri A (2019) Current and future treatments in Alzheimer’s disease. Semin Neurol 39(2):227–240. https://doi.org/10.1055/s-0039-1678581
Bae HR, Kim DH, Park MH, Lee B, Kim MJ, Lee EK, Chung KW, Kim SM, Im DS, Chung HY (2016) β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation. Oncotarget 7(41):66444–66454. https://doi.org/10.18632/oncotarget.12119
Ballard C, Aarsland D, Cummings J et al (2020) Drug repositioning and repurposing for Alzheimer disease. Nat Rev Neurol 16(12):661–673. https://doi.org/10.1038/s41582-020-0397-4
Bandaranayake T, Shaw AC (2016) Host resistance and immune aging. Clin Geriatr Med 32(3):415–432. https://doi.org/10.1016/j.cger.2016.02.007
Barbé-Tuana F, Funchal G, Schmitz CRR, Maurmann RM, Bauer ME (2020) The interplay between immunosenescence and age-related diseases. Semin Immunopathol 42(5):545–557. https://doi.org/10.1007/s00281-020-00806-z
Bauer ME, de la Fuente M (2016) The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence. Mech Ageing Dev. 158:27–37
Beyreuther K, Masters CL (1991) Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer’s disease: precursor-product relationships in the derangement of neuronal function. Brain Pathol 1(4):241–251. https://doi.org/10.1111/j.1750-3639.1991.tb00667.x
Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P (2012) Aging of the human metaorganism: the microbial counterpart. Age (dordr) 34:247–267
Birch J, Passos JF (2017) Targeting the SASP to combat ageing: Mitochondria as possible intracellular allies? Bioessays 39(5)
Blach-Olszewska Z, Zaczynska E, Gustaw-Rothenberg K, Avila-Rodrigues M, Barreto GE, Leszek J, Aliev G (2015) The innate immunity in Alzheimer disease—relevance to pathogenesis and therapy. Curr Pharm Des 21:3582–3588
Block J (2019) Alzheimer’s disease might depend on enabling pathogens which do not necessarily cross the blood-brain barrier. Med Hypotheses 125:129–136
Bolós M, Perea JR, Avila J (2017). Alzheimer’s disease as an inflammatory disease. Biomol Concepts 8(1):37–43. https://doi.org/10.1515/bmc-2016-0029
Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, Frost EH, Fülöp T Jr (2015) β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1. Biogerontology 16:85–98
Bourgade K, Le Page A, Bocti C, Witkowski JM, Dupuis G, Frost EH, Fülöp T Jr (2016) Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model. J Alzheimers Dis 50:1227–1241
Busse M, Michler E, von Hoff F, Dobrowolny H, Hartig R, Frodl T, Busse S (2017) Alterations in the peripheral immune system in dementia. J Alzheimers Dis 58:1303–1313
Cai Z, Yan Y, Wang Y (2013) Minocycline alleviates beta-amyloid protein and tau pathology via restraining neuroinflammation induced by diabetic metabolic disorder. Clin Interv Aging 8:1089–1095. https://doi.org/10.2147/CIA.S46536
Campisi J (2016) Cellular senescence and lung function during aging. Yin and Yang. Ann Am Thorac Soc. 13(Supplement_5):S402.
Caselli M, Trevisani L, Tursi A, Sartori S, Ruina M, Luzzi I, Gaudenzi P, Alvisi V, Gasbarrini G (1997) Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 9(1):45–48
Castellani RJ, Rolston RK, Smith MA (2010) Alzheimer disease. Dis Mon 56:484–546
Castelo-Branco C, Soveral I (2014) The immune system and aging: a review. Gynecol Endocrinol 30(1):16–22. https://doi.org/10.3109/09513590.2013.852531
Cattaneo A, Cattane N, Galluzzi S, Provasi S, Lopizzo N, Festari C, Ferrari C, Guerra UP, Paghera B, Muscio C, Bianchetti A, Volta GD, Turla M, Cotelli MS, Gennuso M, Prelle A, Zanetti O, Lussignoli G, Mirabile D, Bellandi D, Gentile S, Belotti G, Villani D, Harach T, Bolmont T, Padovani A, Boccardi M, Frisoni GB; INDIA-FBP Group (2017) Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 49:60–68. https://doi.org/10.1016/j.neurobiolaging.2016.08.019
Chen RL (2011) Is it appropriate to use albumin CSF/plasma ratio to assess blood brain barrier permeability? Neurobiol Aging 32(7):1338–1339. https://doi.org/10.1016/j.neurobiolaging.2008.08.024
Chiu C, Miller MC, Monahan R, Osgood DP, Stopa EG, Silverberg GD (2015) P-glycoprotein expression and amyloid accumulation in human aging and Alzheimer’s disease: preliminary observations. Neurobiol Aging 36(9):2475–2482. https://doi.org/10.1016/j.neurobiolaging.2015.05.020
Churov AV, Mamashov KY, Novitskaia AV (2020) Homeostasis and the functional roles of CD4(+) Treg cells in aging. Immunol Lett 226:83–89. https://doi.org/10.1016/j.imlet.2020.07.004
Ciarlo E, Heinonen T, Théroude C, Asgari F, Le Roy D, Netea MG, Roger T (2019) Trained immunity confers broad-spectrum protection against bacterial infections. J Infect Dis pii:jiz692
Colonna M, Butovsky O (2017) Microglia function in the central nervous system during health and neurodegeneration. Ann Rev Immunol 26(35):441–468. https://doi.org/10.1146/annurev-immunol-051116-052358
Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J (2018) Senescence-associated secretory phenotypes reveal cell- nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6:2853–2868
Costantini E, D’Angelo C, Reale M (2018) The role of immunosenescence in neurodegenerative diseases. Mediators Inflamm 8(2018):6039171. https://doi.org/10.1155/2018/6039171
Cummings J, Ritter A, Zhong K (2018) Clinical trials for disease-modifying therapies in Alzheimer’s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis 64(s1):S3–S22. https://doi.org/10.3233/JAD-179901
Cunningham C (2013) Microglia and neurodegeneration: the role of systemic inflammation. Glia 61(1):71–90. https://doi.org/10.1002/glia.22350
Dansokho C, Ait Ahmed D, Aid S, Toly-Ndour C, Chaigneau T, Calle V, Cagnard N, Holzenberger M, Piaggio E, Aucouturier P, Dorothée G (2016) Regulatory T cells delay disease progression in Alzheimer-like pathology. Brain 139(Pt 4):1237–1251. https://doi.org/10.1093/brain/awv408
de Kreutzenberg SV, Ceolotto G, Cattelan A, Pagnin E, Mazzucato M, Garagnani P, Borelli V, Bacalini MG, Franceschi C, Fadini GP, Avogaro A (2015) Metformin improves putative longevity effectors in peripheral mononuclear cells from subjects with prediabetes. A randomized controlled trial. Nutr Metab Cardiovasc Dis 25(7):686–693. https://doi.org/10.1016/j.numecd.2015.03.007
de Oliveira SF, Ferreira JV, Plácido J, Sant’Anna P, Araújo J, Marinho V, Laks J, Camaz DA (2019) Three months of multimodal training contributes to mobility and executive function in elderly individuals with mild cognitive impairment, but not in those with Alzheimer’s disease: a randomized controlled trial. Maturitas 126:28–33. https://doi.org/10.1016/j.maturitas.2019.04.217
Di Benedetto S, Müller L, Wenger E, Düzel S, Pawelec G (2017) Contribution of neuroinflammation and immunity to brain aging and the mitigating effects of physical and cognitive interventions. Neurosci Biobehav Rev 75:114–128
Dionisio-Santos DA, Olschowka JA, O’Banion MK (2019) Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease. J Neuroinflammation 16(1):74. 48. https://doi.org/10.1186/s12974-019-1453-0
Domínguez-Andrés J, Fanucchi S, Joosten LAB, Mhlanga MM, Netea MG (2020) Advances in understanding molecular regulation of innate immune memory. Curr Opin Cell Biol 63:68–75
Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J (2019) Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5(1):eaau3333
Eiser AR, Fulop T (2020) Extra-cranial factors in the development of Alzheimer’s disease. Brain Res 1(1748):147076. https://doi.org/10.1016/j.brainres.2020.147076
Ellwardt E, Walsh JT, Kipnis J, Zipp F (2016) Understanding the Role of T Cells in CNS Homeostasis. Trends Immunol 37:154–165
Festoff BW (2016) HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer’s disease. J Neuroinflam 13:194
Floden AM, Combs CK (2011) Microglia demonstrate age-dependent interaction with amyloid-β fibrils. J Alzheimers Dis 25(2):279–293. https://doi.org/10.3233/JAD-2011-101014
Fortier M, Castellano CA, St-Pierre V, Myette-Côté É, Langlois F, Roy M, Morin MC, Bocti C, Fulop T, Godin JP, Delannoy C, Cuenoud B, Cunnane SC (2021) A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement 17(3):543–552. https://doi.org/10.1002/alz.12206
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G (2000) Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 908:244–254
Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, Cevenini E, Castellani GC, Salvioli S (2007) Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128:92–105
Franceschi C, Salvioli S, Garagnani P, de Eguileor M, Monti D, Capri M (2017) Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Front Immunol 8:982
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A (2018a) Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018 Oct;14(10):576–590. https://doi.org/10.1038/s41574-018-0059-4
Franceschi C, Zaikin A, Gordleeva S, Ivanchenko M, Bonifazi F, Storci G, Bonafè M (2018b) Inflammaging 2018: an update and a model. Semin Immunol 40:1–5
Frasca D, Blomberg BB, Paganelli R (2017) Aging, obesity, and inflammatory age-related diseases. Front Immunol 8:1745
Fülöp T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, Pawelec G (2013) Elusive Alzheimer’s disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm. Discov Med 15(80):33–42
Fülöp T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E, Witkowski JM, Pawelec G, Larbi A, Cunnane S (2016) From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. Biogerontology 17(1):147–157. https://doi.org/10.1007/s10522-015-9615-7
Fülöp T, Witkowski JM, Olivieri F, Larbi A (2018a) The integration of inflammaging in age-related diseases. Semin Immunol 40:17–35. https://doi.org/10.1016/j.smim.2018.09.003
Fülöp T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C (2018b) Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front Immunol Jan 10;8:1960. https://doi.org/10.3389/fimmu.2017.01960
Fülöp T, Witkowski JM, Bourgade K, Khalil A, Zerif E, Larbi A, Hirokawa K, Pawelec G, Bocti C, Lacombe G, Dupuis G, Frost EH (2018c) Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer’s disease? Front Aging Neurosci Jul 24;10:224. https://doi.org/10.3389/fnagi.2018.00224
Fülöp T, Larbi A, Witkowski JM (2019) Human inflammaging. Gerontology 65(5):495–504. https://doi.org/10.1159/000497375
Fülöp T, Munawara U, Larbi A, Desroches M, Rodrigues S, Catanzaro M, Guidolin A, Khalil A, Bernier F, Barron AE, Hirokawa K, Beauregard PB, Dumoulin D, Bellenger JP, Witkowski JM, Frost E (2020a) Targeting infectious agents as a therapeutic strategy in Alzheimer’s disease. CNS Drugs 2020 Jul;34(7):673–695. https://doi.org/10.1007/s40263-020-00737-1
Fülöp T, Larbi A, Hirokawa K, Cohen AA, Witkowski JM (2020b) Immunosenescence is both functional/adaptive and dysfunctional/maladaptive. Semin Immunopathol 2020 Oct;42(5):521–536. https://doi.org/10.1007/s00281-020-00818-9
Fülöp T, Tripathi S, Rodrigues S, Desroches M, Bunt T, Eiser A, Bernier F, Beauregard PB, Barron AE, Khalil A, Plotka A, Hirokawa K, Larbi A, Bocti C, Laurent B, Frost EH, Witkowski JM (2021) Targeting impaired antimicrobial immunity in the brain for the treatment of Alzheimer’s disease. Neuropsychiatr Dis Treat 4(17):1311–1339. https://doi.org/10.2147/NDT.S264910
Fülöp T, Dupuis G, Witkowski JM, Larbi A (2016) The role of immunosenescence in the development of age-related diseases. Rev Invest Clin March–April 2016;68(2):84–91
Fyfe I (2021) Dense-core plaques could be beneficial in AD. Nat Rev Neurol 17(6):328. https://doi.org/10.1038/s41582-021-00513-9
Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB (2017) Review: astrocytes in Alzheimer’s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol 43(4):281–298. https://doi.org/10.1111/nan.12338
Gauthier S, Ng KP, Pascoal TA, Zhang H, Rosa-Neto P (2018) Targeting Alzheimer’s disease at the right time and the right place: validation of a personalized approach to diagnosis and treatment. J Alzheimers Dis 64(s1):S23–S31. https://doi.org/10.3233/JAD-179924
Giuliani A, Prattichizzo F, Micolucci L, Ceriello A, Procopio AD, Rippo MR (2017) Mitochondrial (Dys) function in inflammaging: do mitomirs influence the energetic, oxidative, and inflammatory status of senescent cells? Mediators Inflamm 2017:2309034
Giunta B, Fernandez F, Nikolic WV, Obregon D, Rrapo E, Town T, Tan J (2008) Inflammaging as a prodrome to Alzheimer’s disease. J Neuroinflam 11(5):51. https://doi.org/10.1186/1742-2094-5-51
Goldberg EL, Shaw AC, Montgomery RR (2020) How inflammation blunts innate immunity in aging. Interdiscip Top Gerontol Geriatr 43:1–17. https://doi.org/10.1159/000504480 Epub 2020 Apr 9
Goldeck D, Witkowski JM, Fülop T, Pawelec G (2016) Peripheral immune signatures in Alzheimer disease. Curr Alzheimer Res 13(7):739–749
Gupta S (2014) Role of dendritic cells in innate and adaptive immune response in human aging. Exp Gerontol 54:47–52. https://doi.org/10.1016/j.exger.2013.12.009
Han F, Fukunaga K (2009) Beta-amyloid accumulation in neurovascular units following brain embolism. J Pharmacol Sci 111(2):101–109. https://doi.org/10.1254/jphs.09r02cp
Hansen PR (2018) Chronic inflammatory diseases and atherosclerotic cardiovascular disease: innocent bystanders or partners in crime? Curr Pharm Des 24(3):281–290. https://doi.org/10.2174/1381612824666180110102341
Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 12(10):383–388. https://doi.org/10.1016/0165-6147(91)90609-v
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356. https://doi.org/10.1126/science.1072994
Herrup K (2015) The case for rejecting the amyloid cascade hypothesis. Nat Neurosci 18(6):794–799. https://doi.org/10.1038/nn.4017
Hu MY, Lin YY, Zhang BJ, Lu DL, Lu ZQ, Cai W (2019) Update of inflammasome activation in microglia/macrophage in aging and aging-related disease. CNS Neurosci Ther 25(12):1299–1307. https://doi.org/10.1111/cns.13262
Huang Z, Wong LW, Su Y, Huang X, Wang N, Chen H, Yi C (2020) Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease. Front Neuroendocrinol 59:100857. https://doi.org/10.1016/j.yfrne.2020.100857
Humphries F, Fitzgerald KA (2019) Assembling the inflammasome Piece by Piece. J Immunol. 203(5):1093–1094. https://doi.org/10.4049/jimmunol.1900764
Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, Del Tredici K, Field H, Fulop T, Grassi C, Griffin WS, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lövheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg T, Tabet N, Taylor-Robinson SD, Whittum-Hudson JA (2016) Microbes and Alzheimer’s disease. J Alzheimers Dis 51(4):979–984. https://doi.org/10.3233/JAD-160152
Jóźwik A, Landowski J, Bidzan L, Fülop T, Bryl E, Witkowski JM (2012) Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. PLoS One 7(3):e33276. https://doi.org/10.1371/journal.pone.0033276
Kang C (2019) Senolytics and senostatics: a two-pronged approach to target cellular senescence for delaying aging and age-related diseases. Mol Cells 42(12):821–827. https://doi.org/10.14348/molcells.2019.0298
Kelly DJ (1998) The physiology and metabolism of the human gastric pathogen Helicobacter pylori. Adv Microb Physiol 40:137–189
Kern A, Behl C (2009) The unsolved relationship of brain aging and late-onset Alzheimer disease. Biochim Biophys Acta 10:1124–1132. https://doi.org/10.1016/j.bbagen.2009.07.016
Kessler TA (2017) Cervical cancer: prevention and early detection. Semin Oncol Nurs 33(2):172–183
Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Ifrim DC, Saeed S, Jacobs C, van Loenhout J, de Jong D, Stunnenberg HG, Xavier RJ, van der Meer JW, van Crevel R, Netea MG (2012) Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 109:17537–17542
Komleva Y, Chernykh A, Lopatina O, Gorina Y, Lokteva I, Salmina A, Gollasch M (2021) Inflamm-aging and brain insulin resistance: new insights and role of life-style strategies on cognitive and social determinants in aging and neurodegeneration. Front Neurosci 14(14):618395. https://doi.org/10.3389/fnins.2020.618395
Kowalski K, Mulak A (2019) Brain-Gut-Microbiota axis in Alzheimer’s disease. J Neurogastroenterol Motil 25(1):48–60. https://doi.org/10.5056/jnm18087
Kremen WS, Beck A, Elman JA, Gustavson DE, Reynolds CA, Tu XM, Sanderson-Cimino ME, Panizzon MS, Vuoksimaa E, Toomey R, Fennema-Notestine C, Hagler DJ Jr, Fang B, Dale AM, Lyons MJ, Franz CE (2019) Influence of young adult cognitive ability and additional education on later-life cognition. Proc Natl Acad Sci USA 116(6):2021–2026. https://doi.org/10.1073/pnas.1811537116
Kritsilis M, Rizou SV, Koutsoudaki PN, Evangelou K, Gorgoulis VG, Papadopoulos D. (2018) Ageing, cellular senescence and neurodegenerative disease. Int J Mol Sci 19(10), pii:E2937.
Kumar V (2019) Toll-like receptors in the pathogenesis of neuroinflammation. J Neuroimmunol 15(332):16–30. https://doi.org/10.1016/j.jneuroim.2019.03.012
Kumar H, Kawai T, Akira S (2011) Pathogen recognition by the innate immune system. Int Rev Immunol 30(1):16–34. https://doi.org/10.3109/08830185.2010.529976
Kumar DK, Eimer WA, Tanzi RE, Moir RD (2016a) Alzheimer’s disease: the potential therapeutic role of the natural antibiotic amyloid-β peptide. Neurodegener Dis Manag 6(5):345–348
Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, Moir RD (2016b) Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med 8(340):340ra72
Kurakin A, Bredesen DE (2020) Alzheimer’s disease as a systems network disorder: chronic stress/dyshomeostasis, innate immunity, and genetics. Aging (Albany, NY) 12(18):17815–17844. https://doi.org/10.18632/aging.103883
Le Page A, Garneau H, Dupuis G, Frost EH, Larbi A, Witkowski JM, Pawelec G, Fülöp T (2017) Differential phenotypes of myeloid-derived suppressor and T regulatory cells and cytokine levels in amnestic mild cognitive impairment subjects compared to mild alzheimer diseased patients. Front Immunol 7(8):783. https://doi.org/10.3389/fimmu.2017.00783
Le Page A, Dupuis G, Frost EH, Larbi A, Pawelec G, Witkowski JM, Fulop T (2018) Role of the peripheral innate immune system in the development of Alzheimer’s disease. Exp Gerontol 107:59–66
Leszek J, Barreto GE, Gąsiorowski K, Koutsouraki E, Ávila-Rodrigues M, Aliev G (2016) Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: role of brain innate immune system. CNS Neurol Disord Drug Targets 15:329–336
Li L, Zhang X, Yang D, Luo G, Chen S, Le W (2019) Hypoxia increases abeta generation by altering betaand gamma-cleavage of APP. Neurobiol Aging. 30(7):1091–1098. https://doi.org/10.1016/j.neurobiolaging.2007.10.011
Li S, Wang W, Wang C, Tang YY (2010) Possible involvement of NO/NOS signaling in hippocampal amyloid-beta production induced by transient focal cerebral ischemia in aged rats. Neurosci Lett 470(2):106–110. https://doi.org/10.1016/j.neulet.2009.12.064
Licastro F, Pedrini S, Caputo L, Annoni G, Davis LJ, Ferri C, Casadei V, Grimaldi LM (2000) Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain? J Neuroimmunol 103(1):97–102. https://doi.org/10.1016/s0165-5728(99)00226-x
Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179(2):312–339. https://doi.org/10.1016/j.cell.2019.09.001
Lopatko Lindman K, Weidung B, Olsson J, Josefsson M, Kok E, Johansson A, Eriksson S, Hallmans G, Elgh F, Lövheim H (2019) A genetic signature including apolipoprotein Eε4 potentiates the risk of herpes simplex-associated Alzheimer’s disease. Alzheimers Dement (n y). 4(5):697–704. https://doi.org/10.1016/j.trci.2019.09.014
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153(6):1194–1217. https://doi.org/10.1016/j.cell.2013.05.039
Magrone T, Magrone M, Russo MA, Jirillo E (2020) Peripheral immunosenescence and central neuroinflammation: a dangerous liaison—a dietary approach. Endocr Metab Immune Disord Drug Targets 20(9):1391–1411. https://doi.org/10.2174/1871530320666200406123734
Maloney B, Lahiri DK (2016) Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurol 15(7):760–774. https://doi.org/10.1016/S1474-4422(16)00065-X
Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ, Klickstein LB (2014) mTOR inhibition improves immune function in the elderly. Sci Transl Med 6(268):268ra179. https://doi.org/10.1126/scitranslmed.3009892
Marchesi VT (2011) Alzheimer’s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25(1):5–13. https://doi.org/10.1096/fj.11-0102ufm
McGeer PL, McGeer EG (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 126(4):479–497. https://doi.org/10.1007/s00401-013-1177-7
McManus RM, Heneka MT (2017) Role of neuroinflammation in neurodegeneration: new insights. Alzheimers Res Ther. 9(1):14. https://doi.org/10.1186/s13195-017-0241-2
Mehta D, Jackson R, Paul G, Shi J, Sabbagh M (2017) Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs 26(6):735–739. https://doi.org/10.1080/13543784.2017.1323868
Miklossy J (2016) Bacterial amyloid and dna are important constituents of senile plaques: further evidence of the spirochetal and biofilm nature of senile plaques. J Alzheimers Dis 53:1459–1473
Morgan AR, Touchard S, Leckey C, O’Hagan C, Nevado-Holgado AJ, NIMA Consortium, Barkhof F, Bertram L, Blin O, Bos I, Dobricic V, Engelborghs S, Frisoni G, Frölich L, Gabel S, Johannsen P, Kettunen P, Kłoszewska I, Legido-Quigley C, Lleó A, Martinez-Lage P, Mecocci P, Meersmans K, Molinuevo JL, Peyratout G, Popp J, Richardson J, Sala I, Scheltens P, Streffer J, Soininen H, Tainta-Cuezva M, Teunissen C, Tsolaki M, Vandenberghe R, Visser PJ, Vos S, Wahlund LO, Wallin A, Westwood S, Zetterberg H, Lovestone S, Morgan BP (2019) Annex: NIMA–Wellcome trust consortium for neuroimmunology of mood disorders and Alzheimer’s disease. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimers Dement 2019 Jun;15(6):776–787. https://doi.org/10.1016/j.jalz.2019.03.007
Müller L, Di Benedetto S, Pawelec G (2019) The immune system and its dysregulation with aging. Subcell Biochem 91:21–43. https://doi.org/10.1007/978-981-13-3681-2_2
Munafò A, Burgaletto C, Di Benedetto G et al (2020) Repositioning of immunomodulators: a ray of hope for Alzheimer’s disease? Front Neurosci 14:614643. https://doi.org/10.3389/fnins.2020.614643
Myette-Côté É, St-Pierre V, Beaulieu S, Castellano CA, Fortier M, Plourde M, Bocti C, Fulop T, Cunnane SC (2021) The effect of a 6-month ketogenic medium-chain triglyceride supplement on plasma cardiometabolic and inflammatory markers in mild cognitive impairment. Prostaglandins Leukot Essent Fatty Acids 169:102236. https://doi.org/10.1016/j.plefa.2020.102236
Nation DA, Sweeney MD, Montagne A, Sagare AP, D’Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV (2019) Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med Feb 2019;25(2):270–276
Ngandu T, Lehtisalo J, Solomon A, Levälahti E, Ahtiluoto S, Antikainen R, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385(9984):2255–2263. https://doi.org/10.1016/S0140-6736(15)60461-5
Noe CR, Noe-Letschnig M, Handschuh P, Noe CA, Lanzenberger R (2020) Dysfunction of the blood-brain barriers—a key step in neurodegeneration and dementia. Front Aging Neurosci 12:18539
Nyugen J, Agrawal S, Gollapudi S, Gupta S (2010) Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol 30(6):806–813. https://doi.org/10.1007/s10875-010-9448-8
Nzou G, Wicks RT, VanOstrand NR, Mekky GA, Seale SA, El-Taibany A, Wicks EE, Nechtman CM, Marrotte EJ, Makani VS, Murphy SV, Seeds MC, Jackson JD, Atala AJ (2020) Multicellular 3D neurovascular unit model for assessing hypoxia and neuroinflammation induced blood-brain barrier dysfunction. Sci Rep 10(1):9766. https://doi.org/10.1038/s41598-020-66487-8
Osorio C, Kanukuntla T, Diaz E, Jafri N, Cummings M, Sfera A (2019) The post-amyloid era in Alzheimer’s disease: trust your gut feeling. Front Aging Neurosci 11:143
Paouri E, Georgopoulos S (2019) Systemic and CNS inflammation crosstalk: implications for Alzheimer’s disease. Curr Alzheimer Res 16(6):559–574. https://doi.org/10.2174/1567205016666190321154618
Pawelec G (2018) Age and immunity: What is “immunosenescence”? Exp Gerontol 105:4–9. https://doi.org/10.1016/j.exger.2017.10.024
Pawelec G (2020) The human immunosenescence phenotype: does it exist? Semin Immunopathol 42(5):537–544. https://doi.org/10.1007/s00281-020-00810-3
Pawelec G, Bronikowski A, Cunnane SC, Ferrucci L, Franceschi C, Fülöp T, Gaudreau P, Gladyshev VN, Gonos ES, Gorbunova V, Kennedy BK, Larbi A, Lemaître JF, Liu GH, Maier AB, Morais JA, Nóbrega OT, Moskalev A, Rikkert MO, Seluanov A, Senior AM, Ukraintseva S, Vanhaelen Q, Witkowski J, Cohen AA (2020) The conundrum of human immune system “senescence.” Mech Ageing Dev 192:111357. https://doi.org/10.1016/j.mad.2020.111357
Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt Sinai J Med January–February 2010; 77(1):32–42. https://doi.org/10.1002/msj.20157
Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15(5):675–690. https://doi.org/10.1016/j.cmet.2012.04.003
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 9(1):63-75.e2. https://doi.org/10.1016/j.jalz.2012.11.007
Regen F, Hellmann-Regen J, Costantini E, Reale M (2017) Neuroinflammation and Alzheimer’s disease: implications for microglial activation. Curr Alzheimer Res 14(11):1140–1148. https://doi.org/10.2174/1567205014666170203141717
Ricciarelli R, Fedele E (2017) The amyloid cascade hypothesis in Alzheimer’s disease: it’s time to change our mind. Curr Neuropharmacol 15(6):926–935. https://doi.org/10.2174/1570159X15666170116143743
Rivers-Auty J, Mather AE, Peters R, Lawrence CB, Brough D (2020) Anti-inflammatories in Alzheimer’s disease-potential therapy or spurious correlate? Brain Commun 2020 Jul 24;2(2):fcaa109. https://doi.org/10.1093/braincomms/fcaa109
Rodrigue KM, Kennedy KM, Park DC (2009) Beta-amyloid deposition and the aging brain. Neuropsychol Rev 19(4):436–450. https://doi.org/10.1007/s11065-009-9118-x
Rubino G, Bulati M, Aiello A, Aprile S, Gambino CM, Gervasi F, Caruso C, Accardi G (2019) Sicilian centenarian offspring are more resistant to immune ageing. Aging Clin Exp Res 31(1):125–133
Sacks CA, Avorn J, Kesselheim AS (2017) The failure of Solanezumab—How the FDA saved taxpayers billions. N Engl J Med 376(18):1706–1708. https://doi.org/10.1056/NEJMp1701047
Salani F, Sterbini V, Sacchinelli E, Garramone M, Bossù P (2019) Is innate memory a double-edge sword in Alzheimer’s disease? A reappraisal of new concepts and old data. Front Immunol 7(10):1768. https://doi.org/10.3389/fimmu.2019.01768
Salminen A (2020) Activation of immunosuppressive network in the aging process. Ageing Res Rev 57:100998. https://doi.org/10.1016/j.arr.2019.100998
Salvioli S, Monti D, Lanzarini C, Conte M, Pirazzini C, Bacalini MG, Garagnani P, Giuliani C, Fontanesi E, Ostan R, Bucci L, Sevini F, Yani SL, Barbieri A, Lomartire L, Borelli V, Vianello D, Bellavista E, Martucci M, Cevenini E, Pini E, Scurti M, Biondi F, Santoro A, Capri M, Franceschi C (2013) Immune system, cell senescence, aging and longevity–inflamm-aging reappraised. Curr Pharm Des 19(9):1675–1679
Sanada F, Taniyama Y, Muratsu J, Otsu R, Shimizu H, Rakugi H, Morishita R (2018) Source of chronic inflammation in aging. Front Cardiovasc Med. 5:12
Schmitt V, Rink L, Uciechowski P (2013) The Th17/Treg balance is disturbed during aging. Exp Gerontol 48(12):1379–1386. https://doi.org/10.1016/j.exger.2013.09.003
Schubert D, Currais A, Goldberg J, Finley K, Petrascheck M, Maher P (2018) Geroneuroprotectors: effective geroprotectors for the brain. Trends Pharmacol Sci 39(12):1004–1007. https://doi.org/10.1016/j.tips.2018.09.008
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8(6):595–608. https://doi.org/10.15252/emmm.201606210
Shad KF, Aghazadeh Y, Ahmad S, Kress B (2013) Peripheral markers of Alzheimer’s disease: surveillance of white blood cells. Synapse 67(8):541–543
Shen H, Guan Q, Zhang X, Yuan C, Tan Z, Zhai L, Hao Y, Gu Y, Han C (2020) New mechanism of neuroinflammation in Alzheimer’s disease: the activation of NLRP3 inflammasome mediated by gut microbiota. Prog Neuropsychopharmacol Biol Psychiatry 8(100):109884. https://doi.org/10.1016/j.pnpbp.2020.109884
Šimić G, Španić E, Langer Horvat L, Hof PR (2019) Blood-brain barrier and innate immunity in the pathogenesis of Alzheimer’s disease. Prog Mol Biol Transl Sci 168:99–145
Singhrao SK, Olsen I (2019) Assessing the role of Porphyromonas gingivalis in periodontitis to determine a causative relationship with Alzheimer’s disease. J Oral Microbiol 11(1):1563405
Smale ST (2011) Hierarchies of NF-κB target-gene regulation. Nat Immunol 12(8):689–694. https://doi.org/10.1038/ni.2070
Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T (2012) Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 24(5):331–341. https://doi.org/10.1016/j.smim.2012.04.008
Solana C, Tarazona R, Solana R (2018) Immunosenescence of natural killer cells, inflammation, and Alzheimer’s disease. Int J Alzheimers Dis 1(2018):3128758. https://doi.org/10.1155/2018/3128758
Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010) The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 5:e9505
Subhramanyam CS, Wang C, Hu Q, Dheen ST (2019) Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol 94:112–120. https://doi.org/10.1016/j.semcdb.2019.05.004
Tam JH, Pasternak SH (2012) Amyloid and Alzheimer’s disease: inside and out. Can J Neurol Sci 39:286–298. https://doi.org/10.1017/s0317167100013408
Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL (2013) Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 123:966–972
Tejera D, Mercan D, Sanchez-Caro JM, Hanan M, Greenberg D, Soreq H, Latz E, Golenbock D, Heneka MT (2019) Systemic inflammation impairs microglial Abeta clearance through NLRP3 inflammasome. EMBO J 2019 Sep 2;38(17):e101064. https://doi.org/10.15252/embj.2018101064. Epub 2019 Jul 30
Terlecki-Zaniewicz L, Lämmermann I, Latreille J, Bobbili MR, Pils V, Schosserer M, Weinmüllner R, Dellago H, Skalicky S, Pum D, Almaraz JCH, Scheideler M, Morizot F, Hackl M, Gruber F, Grillari J (2018) Small extracellular vesicles and their miRNA cargo are anti-apoptotic members of the senescence-associated secretory phenotype. Aging (Albany, NY) 10(5):1103–1132
Thevaranjan N, Puchta A, Schulz C, Naidoo A, Szamosi JC, Verschoor CP, Loukov D, Schenck LP, Jury J, Foley KP, Schertzer JD, Larché MJ, Davidson DJ, Verdú EF, Surette MG, Bowdish DME (2017) Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host Microbe 21:455
van der Heijden CDCC, Noz MP, Joosten LAB, Netea MG, Riksen NP, Keating ST (2017) Epigenetics and trained immunity. Antioxid Redox Signal 29(11):1023–1040
Walker KA, Ficek BN, Westbrook R (2019) Understanding the role of systemic inflammation in Alzheimer’s disease. ACS Chem Neurosci 10(8):3340–3342. https://doi.org/10.1021/acschemneuro.9b00333
Walton CC, Begelman D, Nguyen W, Andersen JK (2020) Senescence as an amyloid cascade: the amyloid senescence hypothesis. Front Cell Neurosci 19(14):129. https://doi.org/10.3389/fncel.2020.00129
Webers A, Heneka MT, Gleeson PA (2020) The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer’s disease. Immunol Cell Biol 98(1):28–41. https://doi.org/10.1111/imcb.12301
Whalley LJ, Dick FD, McNeill G (2006) A life-course approach to the aetiology of late-onset dementias. Lancet Neurol 5(1):87–96. https://doi.org/10.1016/S1474-4422(05)70286-6
Wissler Gerdes EO, Zhu Y, Tchkonia T, Kirkland JL (2020) Discovery, development, and future application of senolytics: theories and predictions. FEBS J 287(12):2418–2427. https://doi.org/10.1111/febs.15264
Wong C, Goldstein DR (2013) Impact of aging on antigen presentation cell function of dendritic cells. Curr Opin Immunol 25(4):535–541. https://doi.org/10.1016/j.coi.2013.05.016
Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB (2007) Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett 429:95–100
Wozniak MA, Mee AP, Itzhaki RF (2009) Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol 217:131–138
Wyatt-Johnson SK, Brutkiewicz RR (2020) The complexity of microglial interactions with innate and adaptive immune cells in Alzheimer’s disease. Front Aging Neurosci 19(12):592359. https://doi.org/10.3389/fnagi.2020.592359
Yang J, Wise L, Fukuchi KI (2020) TLR4 cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer’s disease. Front Immunol 2020 Apr 23;11:724. https://doi.org/10.3389/fimmu.2020.00724. eCollection 2020
Zhao Y, Zhan JK, Liu Y (2020) A perspective on roles played by immunosenescence in the pathobiology of Alzheimer’s disease. Aging Dis 11(6):1594–1607. https://doi.org/10.14336/AD.2020.0205
Acknowledgements
This work was supported by grants from Canadian Institutes of Health Research (CIHR) (No. 106634) and No. PJT-162366) to AK and TF, the Société des médecins de l’Université de Sherbrooke and the Research Center on Aging of the CIUSSS-CHUS, Sherbrooke and the FRQS Audace grant to TF and EF; by the Polish Ministry of Science and Higher Education statutory grant 02-0058/07/262 to JMW; by Agency for Science Technology and Research (A*STAR) to AL.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
Conflict of Interest
Author declare no conflict of interest.
Ethical Approval
This article does not contain any studies with human participants or animals performed by the author.
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fulop, T. et al. (2022). Immunosenescence and Alzheimer’s Disease. In: Bueno, V., Pawelec, G. (eds) Healthy Longevity and Immune System. Healthy Ageing and Longevity, vol 16. Springer, Cham. https://doi.org/10.1007/978-3-030-87532-9_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-87532-9_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-87531-2
Online ISBN: 978-3-030-87532-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)